PureTech subsidiary Gelesis today touted results from a pivotal weight-loss study of its obesity drug, Gelesis100.
The study met one of its two primary endpoints, with 58% of adults in the treatment arm experiencing clinically-meaningful weight loss of 5% or more.
Get the full story at our sister site, Drug Delivery Business News.
The post Gelesis touts study of hydrogel obesity drug appeared first on MassDevice.
from MassDevice http://ift.tt/2xAx7Co
Cap comentari:
Publica un comentari a l'entrada